Citicoline: study protocols
31 study groups say how much Citicoline participants took a day. These are the doses the studies gave. They are not a recommendation.
Dose per serving from products
282 products in our catalogue print how much Citicoline a serving holds.
Most common: 100 mg to 250 mg, 56% of 282 products.
| Dose per serving | Products |
|---|---|
| 10 mg or less | 5 |
| 10 mg to 25 mg | 11 |
| 25 mg to 50 mg | 37 |
| 50 mg to 100 mg | 22 |
| 100 mg to 250 mg | 157 |
| 250 mg to 500 mg | 29 |
| 500 mg to 1 g | 13 |
| over 1 g | 8 |
Dose per serving from research
31 study groups in 25 studies say how much Citicoline participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 250 mg to 500 mg, 45% of 31 study groups.
| Daily dose | Study groups |
|---|---|
| 100 mg to 250 mg | 3 |
| 250 mg to 500 mg | 14 |
| 500 mg to 1 g | 5 |
| 1 g to 2.5 g | 8 |
| over 2.5 g | 1 |
Commonly used together
3 of 31 study groups took Citicoline with something else, but nothing that 3 or more different studies gave.
31 study groups
| Study | |||
|---|---|---|---|
| Effectiveness of the addition of citicoline to patching in the treatment of amblyopia around visual maturity: a randomized controlled trial 2014 · Group I, patients below five years · Children aged 4–13 years with amblyopia; this dose subgroup was below five years old | 250 mg | 304 days | — |
| Effectiveness of acupuncture for vascular cognitive impairment no dementia: a randomized controlled trial 2019 · oral citicoline · Patients with vascular cognitive impairment no dementia; mean age 65.4 years; sex not specified | 300 mg | 90 days | — |
| A randomized efficacy trial of citicoline in patients with acute ischemic stroke 1999 · citicoline · Adults with acute ischemic stroke in the middle cerebral artery territory and NIHSS ≥5 | 500 mg | 6 weeks | 267 |
| Citicoline and Memory Function in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial 2021 · Citicoline · Men and women aged 50–85 years with age-associated memory impairment (AAMI) | 500 mg | 12 weeks | 49 |
| [The effect of the use of the drug recognan (citicoline) on the state of higher mental functions in patients with mild cognitive impairment] 2021 · Main subgroup (Recognan) · Adults aged 18–50 with mild cognitive impairment | 500 mg | 30 days | 26 |
| [Current treatment options for autonomic, cognitive and emotional disorders in patients with asthenic syndrome treated with recognan (citicoline)] 2019 · main group · Adults aged 18–45 with asthenic syndrome (neurasthenia); men and women | 500 mg | 30 days | 20 |
| Neuroenhancement and neuroprotection by oral solution citicoline in non-arteritic ischemic optic neuropathy as a model of neurodegeneration: A randomized pilot study 2019 · NC Group (OS-Citicoline-treated) · Adults with non-arteritic anterior ischemic optic neuropathy (NAION), age over 45 years; mean age approximately 60 years; women and men | 500 mg | 26 weeks | 19 |
| Effectiveness of the addition of citicoline to patching in the treatment of amblyopia around visual maturity: a randomized controlled trial 2014 · Group I, patients above five years · Children aged 4–13 years with amblyopia; this dose subgroup was above five years old | 500 mg | 304 days | — |
| Citicoline Combination Therapy for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial 2017 · citicoline group · Patients with major depressive disorder receiving citalopram | 200 mg | 6 weeks | — |
| The effect of citicoline oral solution on quality of life in patients with glaucoma: the results of an international, multicenter, randomized, placebo-controlled cross-over trial 2023 · Citicoline oral solution · Adults aged 18 years or older with bilateral moderate open-angle glaucoma and controlled intraocular pressure | 500 mg | 26 weeks | — |
| A randomized dose-response trial of citicoline in acute ischemic stroke patients. Citicoline Stroke Study Group 1997 · 500-mg citicoline group · Adults with acute ischemic stroke | 500 mg | 6 weeks | — |
| Long-term treatment with citicoline may improve poststroke vascular cognitive impairment 2013 · citicoline · Adults with first-ever ischemic stroke; mean age 67.2 years; 56.6% male | 1 g | 1 year | 172 |
| Citicoline improves verbal memory in aging 1996 · Citicoline treatment condition, crossover study · Women and men aged 50–85 years with relatively inefficient memories | 2 g | 60 days | 32 |
| A randomized, double-blind, placebo-controlled trial of citicoline for bipolar and unipolar depression and methamphetamine dependence 2012 · citicoline · Adults with bipolar depression or major depressive disorder and methamphetamine dependence | 2 g | 12 weeks | 28 |
| Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion 1999 · citicoline · Adults aged 57–87 with mild to moderate Alzheimer-type dementia; mean age 76 ± 9 years in this arm | 1 g | 12 weeks | 13 |
| Short-term treatment with citicoline (CDP-choline) attenuates some measures of craving in cocaine-dependent subjects: a preliminary report 1999 · citicoline · Cocaine-dependent subjects with a history of cocaine dependence | 1 g | 2 weeks | — |
| Citicoline (CDP-choline) add-on therapy to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial 2018 · citicoline group · Patients with stable schizophrenia; age and sex not reported | 2.5 g | 8 weeks | — |
| Citicoline improves verbal memory in aging 1996 · Citicoline group, initial study · Women and men aged 50–85 years; older volunteers screened for dementia, memory disorders, and other neurological problems | 1 g | 90 days | — |
| A randomized dose-response trial of citicoline in acute ischemic stroke patients. Citicoline Stroke Study Group 1997 · 2,000-mg citicoline group · Adults with acute ischemic stroke | 2 g | 6 weeks | — |
| Improvements in concentration, working memory and sustained attention following consumption of a natural citicoline-caffeine beverage 2014 · citicoline-caffeine group · Healthy adults aged 20–40, men and women | 250 mg | 1 day | 30 |
| Combining CDP-choline and galantamine: Effects of a selective α7 nicotinic acetylcholine receptor agonist strategy on P50 sensory gating of speech sounds in healthy volunteers 2019 · CDP-choline/galantamine · Healthy adults, stratified into low and high baseline P50 suppressors | 500 mg | 1 day | 30 |
| Targeting alpha-7 nicotinic neurotransmission in schizophrenia: a novel agonist strategy 2013 · galantamine/CDP-choline · Men and women aged 18–70 with schizophrenia or schizoaffective disorder and predominantly negative symptoms, maintained on stable second-generation antipsychotic medication | 2 g | 16 weeks | 19 |
| Effect of oral CDP-choline on plasma choline and uridine levels in humans 2000 · CDP-choline 500 mg · Mildly hypertensive, otherwise normal fasting subjects; age and sex not reported | 500 mg | 1 day | 12 |
| Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Citicoline 010 Investigators 2000 · citicoline-treated patients · Patients with acute ischemic stroke, symptom onset within 24 hours, NIHSS score of 5 or higher, and cerebral gray-matter lesions of 1 to 120 cc on DWI | 500 mg | 6 weeks | 41 |
| Effects of acute CDP-choline treatment on resting state brain oscillations in healthy volunteers 2015 · low dose · healthy male volunteers | 500 mg | 1 day | 24 |
| Chronic citicoline increases phosphodiesters in the brains of healthy older subjects: an in vivo phosphorus magnetic resonance spectroscopy study 2002 · Citicoline for both 6-week periods · Healthy older subjects | 500 mg | 12 weeks | — |
| Effect of oral CDP-choline on plasma choline and uridine levels in humans 2000 · CDP-choline 2000 mg · Mildly hypertensive, otherwise normal fasting subjects; age and sex not reported | 2 g | 1 day | 12 |
| Effect of oral CDP-choline on plasma choline and uridine levels in humans 2000 · CDP-choline 4000 mg · Mildly hypertensive, otherwise normal fasting subjects; age and sex not reported | 4 g | 1 day | 12 |
| Effects of acute CDP-choline treatment on resting state brain oscillations in healthy volunteers 2015 · moderate dose · healthy male volunteers | 1 g | 1 day | 24 |
| Effects of cytidine-5'-diphosphate choline on gray matter volumes in methamphetamine-dependent patients: A randomized, double-blind, placebo-controlled study 2021 · CDP-choline group · Adults aged 18–55 with methamphetamine dependence and recent methamphetamine use | 2 g | 8 weeks | 22 |
| Cytidine-5'-diphosphocholine (Citicoline): a pilot study in patients with non-arteritic ischaemic optic neuropathy 2008 · T-NION (Citicoline) · Patients with non-arteritic ischaemic optic neuropathy, at least 6 months after onset; age range and sex not stated | 1.6 g | 60 days | 14 |